NCT04948372

Effects of Terlipressin on Renal Perfusion in Patients With Septic Shock

Effects of Terlipressin Added to Usual Care vs. Usual Care Alone on Renal Perfusion in Patients With Septic Shock

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Southeast University, China · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This open-label, randomized controlled trial aimed to investigate the effect of a fixed dose of terlipressin added to usual care vs. usual care alone on renal perfusion in patients with septic shock.

Detailed description

Terlipressin is a synthetic vasopressin analog with great affinity to the V1 receptor (vasoconstrictive effect), and could selectively contract efferent arterioles, increase glomerular filtration pressure and renal perfusion. The investigators conducted this open-label, randomized controlled trial to observe the effects of a fixed dose of terlipressin added to usual care vs. usual care alone on renal perfusion in patients with septic shock. Renal perfusion was monitored by renal contrast-enhanced ultrasound. The primary outcome was peak intensity (renal perfusion parameter) at 24 hours after enrollment.

Conditions

• Septic Shock

Interventions

Type	Name	Description
DRUG	Terlipressin treatment	Patients in the terlipressin group received a fixed dose of terlipressin added to usual care. Terlipressin was intravenously pumped at a fixed dose of 1.3μg/kg/hour for 24 hours.
DRUG	Usual care	Patients in the usual care group were treated with standard care, according to the international guidelines for the management of sepsis and septic shock.

Timeline

• Start date: 2019-09-01
• Primary completion: 2020-05-31
• Completion: 2020-06-28
• First posted: 2021-07-01
• Last updated: 2021-07-01

Locations

1 site across 1 country: China